المؤلفون: Helio P, Guimarães, Renato D, Lopes, Pedro G M, de Barros E Silva, Idelzuita L, Liporace, Roney O, Sampaio, Flávio, Tarasoutchi, Conrado R, Hoffmann-Filho, Rodrigo, de Lemos Soares Patriota, Tiago L L, Leiria, Diana, Lamprea, Dalton B, Precoma, Fernando A, Atik, Fabio S, Silveira, Fabio R, Farias, Diogo O, Barreto, Adail P, Almeida, Alexandre C, Zilli, João D, de Souza Neto, Margaret A, Cavalcante, Fernando A M S, Figueira, Flávia C S, Kojima, Lucas, Damiani, Renato H N, Santos, Nanci, Valeis, Viviane B, Campos, Jose F K, Saraiva, Francisco H, Fonseca, Ibraim M, Pinto, Carlos C, Magalhães, Joao F M, Ferreira, John H, Alexander, Ricardo, Pavanello, Alexandre B, Cavalcanti, Otavio, Berwanger, Joima, Tobias

المصدر: New England Journal of Medicine. 383:2117-2126

مصطلحات موضوعية: Male, medicine.medical_specialty, Hemorrhage, 030204 cardiovascular system & hematology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Rivaroxaban, Randomized controlled trial, law, Internal medicine, Mitral valve, Atrial Fibrillation, medicine, Humans, Single-Blind Method, cardiovascular diseases, 030212 general & internal medicine, Stroke, Aged, Bioprosthesis, business.industry, Warfarin, Anticoagulants, Atrial fibrillation, General Medicine, Middle Aged, medicine.disease, Confidence interval, medicine.anatomical_structure, Cardiovascular Diseases, Heart failure, Cardiology, Mitral Valve, Female, business, Factor Xa Inhibitors, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89551d08a2baf22990ddd6212d2c443c
https://doi.org/10.1056/nejmoa2029603